[1140] Strategic Acquisition Opportunity MedTech & Nutraceutical Innovator

Industry-leading Biotech and Nutraceutical Business for Sale - Australian Biotech Company for Sale - Nutraceutical Business Acquisition - Microbiome Technology Business

A rare chance exists to acquire a pioneering MedTech and nutraceutical enterprise at the forefront of microbiome and DNA technologies. Established for over a decade, this business has built a reputation as a trusted leader in functional pathology and personalised health solutions.

With a robust patent portfolio (including US and EU approvals) and a proprietary curated database delivering clinically validated testing protocols with 99.9% accuracy, the business is uniquely positioned to capitalise on the global surge in gut health, immune support, and precision medicine.

Key Highlights:
* Multiple revenue streams: diagnostic testing, product validation, licensing, R&D partnerships, and practitioner education.
* Market-ready formulations: IBS, autism spectrum, and government/aviation resilience products with annuity-style revenue potential.
* Global scalability: International entity structure enabling seamless access to North American and European markets.
* Strategic partnerships: Accredited facilities across Australia, Canada, and the US, plus established government and institutional relationships.
* Lean, asset-light model: No heavy equipment investment required, ensuring high margins and agility.

Income Potential: While current Net Profit After Tax (NPAT) is $719,614, the true value lies in the pipeline. Conservative modelling shows that even fractional adoption of its patented formulations could generate annual gross profits exceeding $150 million, with high-growth scenarios projecting over $600 million.

Global Market Snapshot:
* Wellness market valued at $1.5 trillion, growing 510% annually.
* Probiotics market valued at USD 87.7 billion (2023), forecast CAGR 14.1% through 2030.
* Immune health supplements market valued at USD 26.6 billion (2023), forecast CAGR 10.7% through 2030.

Independently valued at $29.74M, this business offers extraordinary upside for strategic acquirers with established distribution networks. With the right partner, its pipeline of patented products and validated technologies can be rapidly commercialised to capture a share of these booming global markets.

EXCLUSIVE LISTING WITH NATIONAL BUSINESS SALES & VALUATIONS (Internal Ref: 1140)

Please contact Sam on 1300 89 88 87 to complete confidentiality agreement and receive more information.  
Information will be only supplied to QUALIFIED GENUINE BUYERS.

Disclaimer:
The financial information provided is based solely on vendor statements. National Business Sales & Valuations makes no guarantee regarding the accuracy or veracity of these statements and will not be held liable for them. We strongly advise all prospective buyers to conduct their own due diligence and obtain independent legal, financial, and accounting advice. The image used is for illustrative purposes only and does not depict the actual business.